TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35610666

Group type: EXPERIMENTAL
Intervention: GeneXpert® point‐of‐care diagnostic testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, with same‐day treatment for detected infection(s). Arm 1 will additionally receive a test‐of‐cure 3 weeks post‐treatment, while Arm 2 will receive a repeat test at 30‐34 weeks' gestation.
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Syndromic management (standard‐of‐care)
Number of subjects: 2500
Study: 33750369

Group type: EXPERIMENTAL
Intervention: Smoking initiation
Number of subjects: 588190

Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption
Number of subjects: 588190

Group type: COMPARATOR
Intervention: Age at initiation of regular smoking, cigarettes per day, and smoking cessation
Number of subjects: 588190
Study: 32604436

Group type: EXPERIMENTAL
Intervention: Psychoeducational and cognitive-behavioral counseling (8 sessions, 1.5 hours each, 2 sessions per week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Psychoeducational and cognitive-behavioral counseling
Number of subjects: 70
Study: 36099496

Group type: EXPERIMENTAL
Intervention: Pancreatic stent placement (PS)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac (NSAID) 50 mg
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Both pancreatic stent placement and rectal NSAIDs (PS + NSAID)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 321
Study: 33476774

Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel model of collaborative care
Number of subjects: 0
Study: 32320533

Group type: EXPERIMENTAL
Intervention: RAINBOW intervention
Number of subjects: 409

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 409
Study: 36194613

Group type: EXPERIMENTAL
Intervention: Parallel cable configuration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multi cable configuration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Overall preference
Number of subjects: 12
Study: 33629812

Group type: EXPERIMENTAL
Intervention: 24 mg day-1 xanthohumol for eight weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 30
Study: 32862830

Group type: EXPERIMENTAL
Intervention: 1 dose of RBX2660 via enema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 doses of RBX2660 via enema
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32875946

Group type: EXPERIMENTAL
Intervention: Potassium hydroxide 5% solution (KOH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5-fluorouracil cream (5-FU)
Number of subjects: 18
Study: 34836002

Group type: EXPERIMENTAL
Intervention: MIPS before training and CHO plus protein after training (PRE-MIPS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CHO plus protein plus MIPS after training (POST-MIPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CHO plus protein after training (CG)
Number of subjects: 30
Study: 35859087

Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 33474700

Group type: EXPERIMENTAL
Intervention: Manual Pressure Release (MPR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electrical Neuromodulation (ENM)
Number of subjects: 20
Study: 32054509

Group type: EXPERIMENTAL
Intervention: 4-week oral Phe administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4-week placebo administration
Number of subjects: 30
Study: 35239109

Group type: EXPERIMENTAL
Intervention: Clinic BP measurements
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Home BP measurements
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Kiosk BP measurements
Number of subjects: 510
Study: 33070469

Group type: EXPERIMENTAL
Intervention: Propofol (10 mg/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (20% intralipid)
Number of subjects: 40
Study: 36235623

Group type: EXPERIMENTAL
Intervention: Alpha-Glycerylphosphorylcholine (A-GPC) 1000 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34526004

Group type: EXPERIMENTAL
Intervention: SP with VRNET
Number of subjects: 95

Group type: COMPARATOR
Intervention: SP
Number of subjects: 95
Study: 32530769

Group type: EXPERIMENTAL
Intervention: Cisplatin plus FU (60 mg/m2 on day 1 and 1,000 mg/m2 on days 1-4 every 21 days for 24 weeks)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel (AUC 5 on day 1 and 80 mg/m2 on days 1, 8, and 15 every 28 days for 24 weeks)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cisplatin plus FU
Number of subjects: 91

Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel
Number of subjects: 91
Study: 35459000

Group type: EXPERIMENTAL
Intervention: Vibrotactile sensory augmentation (SA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study: 34529887

Group type: EXPERIMENTAL
Intervention: Multimodal preemptive analgesia (flurbiprofen axetil and oxycodone before skin incision combined with bilateral transverse abdominis plane block)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Multimodal preemptive analgesia
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (sufentanil and flurbiprofen axetil combined with bilateral TAPB in PACU)
Number of subjects: 108
Study: 33894218

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: self-selected speed (SSS) of gait
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Activities-specific Balance Confidence (ABC) scale
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Area Deprivation Index (ADI)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: steps per day (SPD)
Number of subjects: 283
Study: 32558314

Group type: EXPERIMENTAL
Intervention: Antimicrobial peptide KSL‐W formulated as an antiplaque chewing gum (APCG), 30 mg, administered three times per day for four days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 26
Study: 35279155

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34663123

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group-based delivery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Remote delivery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall program rating
Number of subjects: 54
Study: 35526272

Group type: EXPERIMENTAL
Intervention: High dose adalimumab regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed dosing regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab exposure
Number of subjects: 0
Study: 33004464

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 and 25 mg)
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 36435427

Group type: EXPERIMENTAL
Intervention: AI-optimized weekly interventions (combination of expert-led group, expert-led call, paraprofessional-led call, and automated message)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Gold standard condition (12 months of weekly BWL groups)
Number of subjects: 336
Study: 34401332

Group type: EXPERIMENTAL
Intervention: puboprostatic ligament-sparing RARP (Group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: standard RARP (Group A)
Number of subjects: 92
Study: 34544626

Group type: EXPERIMENTAL
Intervention: Reminders+LIA
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Combined+LIA
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Vouchers
Number of subjects: 460
Study: 33141417

Group type: EXPERIMENTAL
Intervention: Tai Chi plus normal care
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 67
Study: 34643713

Group type: EXPERIMENTAL
Intervention: Healthy dietary guidelines (HDG)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Green-MED diet
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Men (sex-stratified analysis)
Number of subjects: 294
Study: 33935074

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 120
Study: 33155305

Group type: EXPERIMENTAL
Intervention: 24-week multicomponent program (group exercise, nutritional supplementation, management of depression, deprescribing, home hazard reduction)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 383
Study: 35879748

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 33588293

Group type: EXPERIMENTAL
Intervention: Smartphone laparoscopy simulator (SimuSurg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no laparoscopic activity)
Number of subjects: 30
Study: 32811637

Group type: EXPERIMENTAL
Intervention: Fixed-dose of nine sessions of MET/CBT
Number of subjects: 87

Group type: COMPARATOR
Intervention: PRN condition with smaller initial dose of treatment
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both treatments (MET/CBT and PRN)
Number of subjects: 87
Study: 33884468

Group type: EXPERIMENTAL
Intervention: Abnormal myocardial perfusion scintigraphy (MPS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Normal myocardial perfusion scintigraphy (MPS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Completely normal MPS (SSS and SDS = 0)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Abnormal MPS with revascularization
Number of subjects: 400
Study: 33543228

Group type: EXPERIMENTAL
Intervention: Nd:YAP laser combined with periodontal regeneration surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional periodontal regeneration surgery alone
Number of subjects: 48
Study: 34714961

Group type: EXPERIMENTAL
Intervention: Microneedling with a dermapen
Number of subjects: 62

Group type: COMPARATOR
Intervention: Point-by-point technique injection
Number of subjects: 62
Study: 34001032

Group type: EXPERIMENTAL
Intervention: Invasive strategy (n=1681)
Number of subjects: 3339

Group type: COMPARATOR
Intervention: Conservative strategy (n=1658)
Number of subjects: 3339

Group type: EXPERIMENTAL
Intervention: Paired catheterization data (n=259)
Number of subjects: 3339
Study: 32969391

Group type: EXPERIMENTAL
Intervention: Mometasone furoate intranasal spray
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral montelukast
Number of subjects: 126
Study: 34628065

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 36116287

Group type: EXPERIMENTAL
Intervention: BIVA guided ultrafiltration (UF) adjustment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional clinical parameters for UF adjustment
Number of subjects: 65
Study: 34805810

Group type: EXPERIMENTAL
Intervention: PB-201 50+50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PB-201 100+50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PB-201 100+100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 33013035

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 60
Study: 32943158

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 5190
Study: 32516497

Group type: EXPERIMENTAL
Intervention: Home-use microneedle device only
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of home-use microneedle device and 5% minoxidil solution
Number of subjects: 29

Group type: COMPARATOR
Intervention: 5% minoxidil topical solution only
Number of subjects: 29
Study: 32169887

Group type: EXPERIMENTAL
Intervention: Higher CML-AGE intake
Number of subjects: 1592
Study: 34861168

Group type: EXPERIMENTAL
Intervention: ianalumab 5 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ianalumab 50 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ianalumab 300 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 35623816

Group type: EXPERIMENTAL
Intervention: Stevia (15.3 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: d-tagatose (5000 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (60 mL water)
Number of subjects: 33
Study: 33141487

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (historical cohort)
Number of subjects: 9
Study: 33610836

Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 mg/50 μl)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: aflibercept (2.0 mg/50 μl)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: bevacizumab (1.25 mg/50 μl)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 267
Study: 33677048

Group type: EXPERIMENTAL
Intervention: Involved-field irradiation with definitive chemoradiation therapy (61.2 Gy in 34 fractions using intensity modulated radiation therapy)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Involved-field irradiation with definitive chemoradiation therapy
Number of subjects: 436
Study: 33216008

Group type: EXPERIMENTAL
Intervention: Web-based alcohol intervention
Number of subjects: 306
Study: 33143451

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35195337

Group type: EXPERIMENTAL
Intervention: Higher strength of uterine contractions
Number of subjects: 0
Study: 34018426

Group type: EXPERIMENTAL
Intervention: Very young candidates (< 35 years old)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Male candidates
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Female candidates
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Perceived attractiveness and warmth
Number of subjects: 93
Study: 36030811

Group type: EXPERIMENTAL
Intervention: Telemedicine group (asynchronous online consultation, 200 mg mifepristone and 800 μg misoprostol at home)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard care group (in-person consultation, 200 mg mifepristone in clinic and 800 μg misoprostol at home)
Number of subjects: 900
Study: 33270092

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36045818

Group type: EXPERIMENTAL
Intervention: 400 μg of rectal misoprostol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 400 μg of sublingual misoprostol
Number of subjects: 128

Group type: COMPARATOR
Intervention: 30 units of oxytocin (control)
Number of subjects: 128
Study: 35666231

Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 26.1/5.2 mg (Treatment A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 39.2/7.8 mg (Treatment B)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 52.3/10.4 mg (Treatment C)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 52.3/10.4 mg (multiple dosing)
Number of subjects: 23
Study: 33767064

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (specific types not mentioned)
Number of subjects: 5868

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (dapagliflozin)
Number of subjects: 5868

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (empagliflozin)
Number of subjects: 5868

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5868
Study: 35807922

Group type: EXPERIMENTAL
Intervention: Graded Protein (GP) diet (0.8 g/kg/d at week 1 to 2.2 g/kg/d at week 10 with whey protein supplement)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Constant Protein (CP) diet (0.8-1.0 g/kg/d with no protein supplement)
Number of subjects: 18
Study: 34849260

Group type: EXPERIMENTAL
Intervention: Building Up Trial intervention
Number of subjects: 225
Study: 33206251

Group type: EXPERIMENTAL
Intervention: Moderate‐intensity aerobic training (MOD T)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High‐intensity aerobic training (HIGH T)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study: 32453870

Group type: EXPERIMENTAL
Intervention: pep_RTE62G
Number of subjects: 0
Study: 33715655

Group type: EXPERIMENTAL
Intervention: Solid alloy 80% Cu-20% Ni (integral copper)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Spray-on 80% Cu-20% Ni (spray-on)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 16% composite copper-impregnated surface (CIS)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control surgical grade (AISI 316) stainless steel
Number of subjects: 480
Study: 34412070

Group type: EXPERIMENTAL
Intervention: Gefitinib treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cdc42/Rac1 inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAK1 downregulation
Number of subjects: 0
Study: 33142773

Group type: EXPERIMENTAL
Intervention: Foreign Language Learning (FLL)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Group (Young Adults)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control Group (Elderly)
Number of subjects: 105
Study: 36007980

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol
Number of subjects: 648

Group type: COMPARATOR
Intervention: Maintenance budesonide plus SABA
Number of subjects: 648
Study: 33853098

Group type: EXPERIMENTAL
Intervention: Foot massages
Number of subjects: 66
Study: 35511858

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Non-caloric restriction (NoCR)
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) with exercise
Number of subjects: 1343
Study: 33780463

Group type: EXPERIMENTAL
Intervention: Arabin pessary in addition to standard care (n=250)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Standard care alone (n=253)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Cervical pessary (meta-analysis of 4 studies, 313 women)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Arabin pessary group (n=250)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Standard treatment group (n=253)
Number of subjects: 503
Study: 33079877

Group type: EXPERIMENTAL
Intervention: Continuous invasive arterial pressure monitoring
Number of subjects: 152

Group type: COMPARATOR
Intervention: Intermittent oscillometric blood pressure monitoring
Number of subjects: 152
Study: 35581710

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transversus Abdominis Plane (TAP) Block
Number of subjects: 60
Study: 33888542

Group type: EXPERIMENTAL
Intervention: Famine-exposed group (1959-1962)
Number of subjects: 2171
Study: 32954927

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 5637

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 5637
Study: 34931699

Group type: EXPERIMENTAL
Intervention: Pharmacist-led interdisciplinary intervention
Number of subjects: 221
Study: 34339598

Group type: EXPERIMENTAL
Intervention: Losartan for 48 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 220
Study: 35120288

Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 33027550

Group type: EXPERIMENTAL
Intervention: High-intensity hybrid-functional electrical stimulation rowing for 6 months
Number of subjects: 40
Study: 36414580

Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti Technique
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard Ponseti Technique
Number of subjects: 104
Study: 32076698

Group type: EXPERIMENTAL
Intervention: Low density lipoprotein (LDL)-cholesterol
Number of subjects: 432173

Group type: EXPERIMENTAL
Intervention: High density lipoprotein (HDL)-cholesterol
Number of subjects: 432173

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 432173

Group type: COMPARATOR
Intervention: Negative control outcomes (aortic regurgitation and mitral regurgitation)
Number of subjects: 432173
Study: 35475948

Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (particle mass concentrations around 300 µg/m3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined exposure to diesel exhaust and high traffic noise (75 dB(A))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered (clean) air exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Noise exposure only (46 dB(A))
Number of subjects: 18
Study: 33325216

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation strategy (G1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional ventilation strategy (G0)
Number of subjects: 100
Study: 34410203

Group type: EXPERIMENTAL
Intervention: Group CBT treatment
Number of subjects: 48
Study: 34188527

Group type: EXPERIMENTAL
Intervention: PCV-VG
Number of subjects: 64

Group type: COMPARATOR
Intervention: VCV
Number of subjects: 64
Study: 36471268

Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Assessment-only control condition (AC)
Number of subjects: 330
Study: 33884269

Group type: EXPERIMENTAL
Intervention: Nebulizer position between the tracheal tube and Y‐piece (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nebulizer position at the inspiratory limb near the ventilator water cup (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nebulizer position between the ventilator inlet and the heated humidifier (Group C)
Number of subjects: 75